Investor reports 7.5% stake in Catheter Precision
Catheter Precision, Inc. investor Joseph Reda filed a Schedule 13G reporting a significant ownership position in the company’s common stock.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Catheter Precision, Inc. investor Joseph Reda filed a Schedule 13G reporting a significant ownership position in the company’s common stock. He beneficially owns 176,674 shares, representing 7.5% of the outstanding common stock, with sole voting and dispositive power over all these shares.
The 7.5% figure is based on 2,357,127 Catheter Precision common shares outstanding as verified with the issuer on February 11, 2026. Reda certifies that the securities were not acquired and are not held for the purpose of changing or influencing control of Catheter Precision.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What ownership stake in Catheter Precision (VTAK) does Joseph Reda report?
How was Joseph Reda’s 7.5% ownership in Catheter Precision (VTAK) calculated?
Does Joseph Reda seek to influence control of Catheter Precision (VTAK)?
What type of SEC filing did Joseph Reda submit for Catheter Precision (VTAK)?
When did the ownership event triggering this Schedule 13G for Catheter Precision (VTAK) occur?
AI-generated analysis. How Rhea-AI works. Not financial advice.